Bridgefront Capital, LLC Editas Medicine, Inc. Transaction History

Bridgefront Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $51,155 - $79,745	10,954 New	10,954 $51,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $143,742 - $259,233	22,601 Added 73.57%	53,320 $438,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $215,954 - $354,190	30,719 New	30,719 $222,000
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $205,074 - $371,218	-6,554 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $29,067 - $66,304	732 Added 12.57%	6,554 $275,000
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $157,601 - $491,085	5,822 New	5,822 $408,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $183M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.